Study Comparing Tapinarof Cream 1% to VTAMA ® (Tapinarof Cream 1%) in the Treatment of Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 560
- Registration Number
- NCT06742957
- Locations
- 🇺🇸
Site 12103, College Station, Texas, United States
🇺🇸Site 12117, Houston, Texas, United States
🇺🇸Site 12109, Las Vegas, Nevada, United States
Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 1050
- Registration Number
- NCT05617820
- Locations
- 🇺🇸
Site 10135, San Diego, California, United States
🇺🇸Site 10111, Las Vegas, Nevada, United States
🇺🇸Site 10146, Chandler, Arizona, United States
Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris
- Conditions
- Interventions
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 807
- Registration Number
- NCT05550337
- Locations
- 🇺🇸
Site 10006, El Paso, Texas, United States
🇺🇸Site 10011, New Orleans, Louisiana, United States
🇺🇸Site 10008, Las Cruces, New Mexico, United States
Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria
- Conditions
- Interventions
- First Posted Date
- 2021-07-26
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 608
- Registration Number
- NCT04976192
- Locations
- 🇺🇸
10014, Maitland, Florida, United States
🇺🇸10008, Bakersfield, California, United States
🇺🇸Site 10001, Clearwater, Florida, United States
A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis
- Conditions
- Interventions
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 332
- Registration Number
- NCT04729621
- Locations
- 🇺🇸
Teva Site 107, New London, Connecticut, United States
🇺🇸Teva Site 119, Tucson, Arizona, United States
🇺🇸Teva Site 115, Coral Gables, Florida, United States
An Open-Label, Single-Center Study to Evaluate the Exposure-Response Relationship Between the Plasma Drug Concentrations and the Change From Baseline in QTc at Steady State Following Once-daily Administration of CASSIPA® in Opioid Dependent Subjects.
- Conditions
- Interventions
- First Posted Date
- 2019-09-12
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Teva Pharmaceuticals USA
- Registration Number
- NCT04088266
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp
- First Posted Date
- 2015-11-23
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 492
- Registration Number
- NCT02611804
- Locations
- 🇺🇸
Tampa Bay Medical Research, Clearwater, Florida, United States
🇺🇸Greenville Dermatology, Greenville, South Carolina, United States
🇺🇸Clinical Science Institute, Santa Monica, California, United States
Clinical Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 137/50 mcg Nasal Spray to Dymista™
- Conditions
- Interventions
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 1535
- Registration Number
- NCT02249663
- Locations
- 🇺🇸
Novum Pharmaceutical Research Services, Pittsburgh, Pennsylvania, United States
Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuation vs. Flonase in Allergic Rhinitis Patients
- Conditions
- Interventions
- First Posted Date
- 2014-09-23
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 1474
- Registration Number
- NCT02246920
- Locations
- 🇺🇸
Novum Pharmaceutical Research Services, Pittsburgh, Pennsylvania, United States
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
- Conditions
- Interventions
- First Posted Date
- 2012-09-17
- Last Posted Date
- 2020-11-24
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 589
- Registration Number
- NCT01686152
- Locations
- 🇺🇸
Encino Research Center, Encino, California, United States
🇺🇸Northern California Research, Sacramento, California, United States
🇺🇸Longmont Clinic, PC, Longmont, Colorado, United States